Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For hematologic malignancies receiving myelotoxic therapy in the setting of autologous…. Sold as Kepivance. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Palifermin (sold as Kepivance), first approved Dec 15, 2004, with 1 new use approved and 0 published complete response letters.
First approved: Dec 15, 2004
Applications: 1
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $114K
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
KEPIVANCE
Part B
$114K
New
0
Clinical Trials
11 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
